JP2006522062A - 神経学的障害の処置のための抗癲癇剤を含む組み合わせ - Google Patents

神経学的障害の処置のための抗癲癇剤を含む組み合わせ Download PDF

Info

Publication number
JP2006522062A
JP2006522062A JP2006504970A JP2006504970A JP2006522062A JP 2006522062 A JP2006522062 A JP 2006522062A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006522062 A JP2006522062 A JP 2006522062A
Authority
JP
Japan
Prior art keywords
combination
combination according
administered
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522062A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド・エイトケン
クルト・リンゲンヘール
マルクス・シュムッツ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2006522062A publication Critical patent/JP2006522062A/ja
Publication of JP2006522062A5 publication Critical patent/JP2006522062A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2006504970A 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ Pending JP2006522062A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2006522062A true JP2006522062A (ja) 2006-09-28
JP2006522062A5 JP2006522062A5 (cg-RX-API-DMAC7.html) 2007-05-17

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504970A Pending JP2006522062A (ja) 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ

Country Status (10)

Country Link
US (1) US20060194766A1 (cg-RX-API-DMAC7.html)
EP (1) EP1620103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006522062A (cg-RX-API-DMAC7.html)
CN (1) CN100546581C (cg-RX-API-DMAC7.html)
AU (1) AU2004226825B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409170A (cg-RX-API-DMAC7.html)
CA (1) CA2521274A1 (cg-RX-API-DMAC7.html)
GB (1) GB0307860D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010707A (cg-RX-API-DMAC7.html)
WO (1) WO2004087161A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20100168174A1 (en) * 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502681A (ja) * 1996-10-24 2001-02-27 ノバルティス アクチエンゲゼルシャフト 置換アミノアルカンホスホン酸

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
DE69724144D1 (de) * 1996-10-19 2003-09-18 Univ Wales Bangor Verfahren zur herstellung von chemisch reaktiver stärke
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
CA2392879C (en) * 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
IL161700A0 (en) * 2001-11-12 2004-09-27 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502681A (ja) * 1996-10-24 2001-02-27 ノバルティス アクチエンゲゼルシャフト 置換アミノアルカンホスホン酸

Also Published As

Publication number Publication date
AU2004226825A1 (en) 2004-10-14
CN100546581C (zh) 2009-10-07
BRPI0409170A (pt) 2006-04-11
CN1767832A (zh) 2006-05-03
EP1620103A1 (en) 2006-02-01
GB0307860D0 (en) 2003-05-14
AU2004226825B2 (en) 2007-08-16
MXPA05010707A (es) 2005-12-12
US20060194766A1 (en) 2006-08-31
CA2521274A1 (en) 2004-10-14
WO2004087161A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20110046119A1 (en) Therapeutic treatment
TR201806828T4 (tr) Gut ve hiperürisemi tedavisi.
EP2146706B1 (en) Use of dimiracetam in the treatment of chronic pain
US20040072851A1 (en) Medicinal compositions for treating lower uropathy
JP2009539996A (ja) 腎機能障害を持つ個体における利尿改善方法
CN100546581C (zh) 用于治疗神经病学病症的包含抗癫痫药的组合
NZ543109A (en) Method of improved diuresis in individuals with impaired renal function
AU2004290890B2 (en) Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia
JP3598116B2 (ja) 遅発性ジスキネジアの治療用医薬組成物とその利用
KR20050121236A (ko) 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
JPWO2019181854A1 (ja) てんかん治療剤
WO2005049042A1 (en) Combinations comprising ampa receptor antagonists for the treatment of tinnitus
WO2005049041A1 (en) Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders
WO2005094797A2 (en) Use of ampa-receptor antagonists for treating dementia
WO2005049039A1 (en) Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders
WO2005039594A1 (en) Combinations comprising ampa receptor antagonists for the treatment of myopia
WO2005039593A1 (en) Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain
HK1090553B (en) A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
HK1187244A (en) Use of dimiracetam in the treatment of chronic pain
EP1932529A1 (en) Method of improved diuresis in individuals with impaired renal function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116